Prima to get $4.7m grant for cancer vaccine
21 March, 2013 by Dylan Bushell-EmblingPrima BioMed (ASX:PRR) will receive a $4.7m grant from Saxony Development Bank and will use the funds to explore the use of CVac in more cancer types beyond ovarian.
New treatment effective for chronic pain
20 March, 2013A new device that stimulates the spinal cord provides relief for patients with difficult-to-treat chronic pain.
Biolife signs cancer vaccine manufacturing deal
19 March, 2013 by Dylan Bushell-EmblingBiolife Science has signed on Pevion Biotech to manufacture its HER-Vaxx anticancer vaccine in preparation for phase II trials in gastric cancer.
Emerging drug resistance in young malaria parasites
18 March, 2013 by Susan WilliamsonThe alarming rate at which the malaria parasite is developing resistance to drugs may be countered by changing the timing of the drug treatment and developing drugs that last longer in the bloodstream.
Biolife Science $5m ASX listing to progress cancer vaccine
14 March, 2013 by Susan WilliamsonAustralian shareholders are being given the opportunity to buy into Biolife Science with a vaccine that shows potential to combat stomach (gastric) and breast cancer.
NHMRC Ethics Award
14 March, 2013 by Susan WilliamsonNominations for the NHMRC 2013 Ethics Award close on 22 March 2013.
Robots play role in dementia treatment
11 March, 2013 by Susan WilliamsonProving the benefits and cost-effectiveness of animal robots in the treatment of dementia is the focus of a Griffith research study.
Anti-ageing protein linked to pancreatic cancer
06 February, 2013 by Tim DeanSirtuin, which is known for its link to ageing, has been associated with pancreatic cancer, raising the prospect of new treatments.
Discovery paves way for new gastric cancer treatment
17 January, 2013 by Tim DeanDrugs that inhibit a protein involved in the growth of colon and gastric cancers could be developed into a new treatment.
Insulin’s molecular handshake caught in the act
10 January, 2013 by Tim DeanResearchers at WEHI have used the Australian Synchrotron to generate the world’s first 3D images of insulin docking with cells, a finding that could lead to improved treatments for diabetes.
BioDiem partner close to filing for vaccine exports
12 December, 2012 by Dylan Bushell-EmblingBioDiem (ASX:BDM) partner Serum Institute of India will file for WHO approval in early 2013 to export flu vaccines based on BioDiem's LAIV platform.
Patrys (ASX:PAB) hits myeloma trial milestone
10 December, 2012 by Dylan Bushell-EmblingPatrys (ASX:PAB) has completed the main round of dosing for the first three patients enrolled in a German trial of its PAT-SM6 antibody in multiple myeloma.
Cavatak shows potential against bladder cancer
29 November, 2012 by Dylan Bushell-EmblingEarly research into Viralytics' (ASX:VLA) Cavatak oncolytic virus shows it effectively targets receptors on bladder cancer tissue.
Getting to the heart of Prader-Willi Syndrome
19 November, 2012 by Tim DeanResearchers at the Garvan Institute have found a sign that the rare genetic disorder, Prader-Willi Syndrome, is linked to problems in the autonomic nervous system.
Comment: Medical research key to improving the health and wealth of Australia
16 November, 2012 by Staff WritersProfessor Brendan Crabb, incoming President of AAMRI, outlines the priorities he sees for health and medical research in Australia at a time of budget cuts and systemic challenges.
